Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
archives
»
Monthly Archive
» March 2013
March 2013
3 Pharmaceutical Stocks to Sell Now
3 Pharmaceutical Stocks to Sell Now
InvestorPlace
Corcept Therapeutics
Vivus
Cempra
Pfizer May Have To Rethink Xalkori Cost Structure
Pfizer May Have To Rethink Xalkori Cost Structure
Seeking Alpha
Pfizer
Xalkori
lung cancer
FDA OKs first-of-a-kind diabetes drug from J&J
FDA OKs first-of-a-kind diabetes drug from J&J
Yahoo/AP
JNJ
diabetes
Invokana
type 2 diabetes
This Pharma's Dividend Is Safe for Now
This Pharma's Dividend Is Safe for Now
Motley Fool
Eli Lilly
Celgene's Star Drug Revlimid And Its Competitors
Celgene's Star Drug Revlimid And Its Competitors
Seeking Alpha
Celgene
Revlimid
Multiple Myeloma
JNJ
Velcade
AbbVie
Bristol-Myers Squibb
elotuzumab
Is This Biotech A Value Stock Or Value Trap?
Is This Biotech A Value Stock Or Value Trap?
Seeking Alpha
Omeros
Questions That Must Be Answered For The Success Of Probuphine
Questions That Must Be Answered For The Success Of Probuphine
Seeking Alpha
Probuphine
opiod addiction
3 Humongous Health-Care Stocks This Week
3 Humongous Health-Care Stocks This Week
Motley Fool
Repros Therapeutics
Endocyte
Sarepta Therapeutics
Biogen prices new MS drug at discount to key competitors
Biogen prices new MS drug at discount to key competitors
Reuters
Biogen
Tecfidera
multiple sclerosis
MS
The Oncology Stock to Buy Today
The Oncology Stock to Buy Today
Motley Fool
ONYX Pharmaceuticals
Pages
1
2
3
4
5
6
7
8
9
…
next ›
last »